文献速递妇科

卵巢癌女性不良围手术期结局风险计算器的开发与验证

Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
PubMed 文献 · Am J Obstet Gynecol · 2019-02-13

本研究利用美国国家手术质量改进计划数据库2011至2015年数据,纳入7029例卵巢、输卵管或原发性腹膜癌手术患者,建立并验证预测严重围手术期并发症或死亡的风险列线图。最终模型纳入≥3项细胞减灭术、ASA分级≥4级、出血性疾病和年龄≥80岁等变量,内部判别一致性指数为0.71。

要点

  • 5.8%患者发生Clavien-Dindo IV级并发症,9.8%再入院,3.0%需再手术,0.9%术后30天内死亡。
  • ≥3项细胞减灭术、ASA≥4级、出血性疾病、年龄≥80岁与严重围手术期并发症或死亡风险独立相关。
  • 列线图内部判别一致性指数0.71,内部验证集预测准确。

核心结论

  • 卵巢癌手术患者发生不良围手术期结局的风险显著,使用易识别的特征,该列线图可以预测不良结局。

研究设计与样本

  • 使用美国国家手术质量改进计划数据库识别2011至2015年接受手术的卵巢、输卵管或原发性腹膜癌女性。
  • 采用多变量模型预测严重围手术期并发症或死亡风险,对缺失数据采用多重插补法。
  • 基于最终模型开发列线图,并用校准图和判别一致性指数评估模型的判别能力。

主要发现

  • 共识别7029例患者,5.8%发生Clavien-Dindo IV级并发症,9.8%再入院,3.0%需再手术,0.9%术后30天内死亡。
  • ≥3项细胞减灭术与严重围手术期并发症或死亡的校正比值比为4.53(95%置信区间3.01-6.82)。
  • ASA分级≥4级的校正比值比为2.89(95%置信区间1.17-7.14)。
  • 出血性疾病的校正比值比为2.73(95%置信区间1.82-4.10)。
  • 年龄≥80岁的校正比值比为2.46(95%置信区间1.66-3.63)。

关键数值与推荐

  • 最终列线图纳入年龄、急诊手术、腹水、出血性疾病、低白蛋白、ASA分级和扩展手术评分等变量。
  • 最终列线图内部判别一致性指数为0.71,内部验证集预测准确,表示在所有可能配对中正确识别患者的比例为71%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary cytoreduction followed by platinum-based chemotherapy is the primary treatment for advanced ovarian cancer. However, neoadjuvant chemotherapy followed by interval debulking is an alternative option, particularly in those who may be poor surgical candidates. OBJECTIVE: The objective of this study was to determine factors associated with short-term, significant perioperative morbidity and mortality for women undergoing surgery for ovarian cancer and to create a nomogram to predict the risk of adverse perioperative outcomes. STUDY DESIGN: We used the National Surgical Quality Improvement Program database to identify women with ovarian, fallopian tube, or primary peritoneal cancer who underwent surgery from 2011 to 2015. Demographic factors, clinical characteristics, comorbidity, functional status, and the extent of surgery were used to predict the risk of severe perioperative complications or death using multivariable models. Multiple imputation methods were employed for missing data. A nomogram was developed based on the final model. The discrimination ability of the model was assessed with a calibration plot and discrimination concordance index. RESULTS: We identified a total of 7029 patients. Overall, 5.8% of patients experienced a Clavien-Dindo IV complication, 9.8% of patients were readmitted, 3.0% of patients required a reoperation, and 0.9% of patients died within 30 days. Among the baseline variables assessed, increasing age, emergent surgery, ascites, bleeding disorder, low albumin, higher American Society of Anesthesiology classification score, and a higher extended procedure score were associated with serious perioperative morbidity or mortality. Of these factors, performance of ≥3 cytoreductive procedures (adjusted odds ratio 4.53, 95% confidence interval 3.01-6.82), American Society of Anesthesiology classification score ≥ class 4 (adjusted odds ratio 2.89, 95% confidence interval 1.17-7.14), bleeding disorder (adjusted odds ratio 2.73, 95% confidence interval 1.82-4.10), and age ≥80 years (adjusted odds ratio 2.46, 95% confidence interval 1.66-3.63) were most strongly associated with risk of an event. The final nomogram included the above variables and had an internal discrimination concordance index of 0.71, with accurate predictions in an internal validation set, indicating a 71% correct identification of patients across all possible pairs. CONCLUSION: Women undergoing surgery for ovarian cancer are at significant risk for the occurrence of adverse perioperative outcomes. Using readily identifiable characteristics, this nomogram can predict adverse outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cham S, Chen L, St Clair CM, et al. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. Am J Obstet Gynecol. 2019. PMID: 30771346. doi:10.1016/j.ajog.2019.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。